Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Dr Sara M. Tolaney on Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer
August 08, 2018
Dr Dennis P. Scanlon on Recent Attempts to Address Clinician Burnout
August 06, 2018
Dr Dennis P. Scanlon Explains Costs Associated With the Opioid Epidemic
July 27, 2018
Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine
July 25, 2018
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23, 2018
Dr Peter Paul Yu Explains Current Challenges With Precision Medicine
July 18, 2018
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 08, 2018
Currently Reading
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Leonard Saltz: Novel Approaches to Colon Cancer, Behaviors That Impact Survival
July 02, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018

Dr Peter Paul Yu on Progress in the Move Toward Interoperability

Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.


Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.

Transcript

How much progress has there been in the move toward interoperability among EHR systems? What efforts are needed to accelerate the shift?

Most people when they talk about interoperability, they talk about it in the way of how do you get it from one electronic health record (EHR) into the other EHR, and that’s relevant, if the patient is moving from Seattle to Kansas City and you need to move records across, and it’s relevant if you were in a cardiologist's office yesterday and today you’re seeing the orthopedic doctor and you need to move it around. That’s generally what people talk about in terms of interoperability.

From an oncologist point of view, I think it’s somewhat different. From an oncologist point of view, I think it’s more about: how do you get the data that’s in an electronic health record connected to the data that’s in the radiation oncologist’s record, which is driving the Linux, and how do you get it connected to the pathology office, which has their detailed pathology report information? How do you move that into the cancer registry, so you can satisfy your reporting requirements? For oncology, it’s not so much about moving it from one EHR to another EHR, its more about how do we aggregate the whole sum of the patient’s cancer experience in a database?

Having defined that, the bad news is that there’s very little going on there because when you’re talking about one EHR to another EHR, there is a basic data set that’s in common to all your charge. The representation and how its captured is different, but the data is, in theory, similar, and you can move it around. And when you take it out of one EHR, you can dump it into another spot, another EHR. When you’re talking about moving things like genomic data from a precision medicine next-generation sequencing test and you have 500 mutations to report on and there’s not a single landing field for each of those mutations in the EHR, now you have a really big problem. So, I think this is an area that we’ve just started the discussion and awareness of, but I’d say right now we’re far from even recognizing the importance of this need.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!